Financial Ratios

ZIM LABORATORIES LTD.

NSE : ZIMLABBSE : 541400ISIN CODE : INE518E01015Industry : Pharmaceuticals & DrugsHouse : MNC
BSE103.39-0.43 (-0.41 %)
PREV CLOSE ( ) 103.82
OPEN PRICE ( ) 103.50
BID PRICE (QTY) 103.74 (1)
OFFER PRICE (QTY) 103.98 (1)
VOLUME 424
TODAY'S LOW / HIGH ( )103.39 104.63
52 WK LOW / HIGH ( )79.5 128.45
NSE103.57-0.22 (-0.21 %)
PREV CLOSE( ) 103.79
OPEN PRICE ( ) 103.36
BID PRICE (QTY) 103.56 (20)
OFFER PRICE (QTY) 103.81 (1)
VOLUME 10450
TODAY'S LOW / HIGH( ) 103.25 104.56
52 WK LOW / HIGH ( )79.49 128.9
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Operational & Financial Ratios
   Earnings Per Share (Rs)2.413.445.138.013.46
   CEPS(Rs)6.496.488.445.724.15
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)49.9047.6039.85104.7396.69
   Tax Rate(%)33.3227.2830.3732.5634.54
Margin Ratios
   Core EBITDA Margin(%)11.5210.9712.9111.5112.12
   EBIT Margin(%)7.728.2010.468.386.41
   Pre Tax Margin(%)4.696.309.065.862.83
   PAT Margin (%)3.134.586.313.951.85
   Cash Profit Margin (%)8.428.6410.378.456.66
Performance Ratios
   ROA(%)2.594.287.383.981.77
   ROE(%)4.947.8613.737.963.64
   ROCE(%)8.3510.1317.4812.028.12
   Asset Turnover(x)0.830.931.171.010.96
   Sales/Fixed Asset(x)1.421.622.171.981.94
   Working Capital/Sales(x)7.496.555.805.967.27
Efficiency Ratios
   Fixed Capital/Sales(x)0.700.620.460.510.51
   Receivable days94.1494.1177.9080.2276.51
   Inventory Days81.4967.4059.3771.8066.56
   Payable days146.27129.81129.58167.28150.70
Valuation Parameters
   PER(x)33.2827.7714.116.656.99
   PCE(x)12.3514.738.589.325.82
   Price/Book(x)1.612.011.821.530.75
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)1.341.561.030.940.63
   EV/Core EBITDA(x)10.2712.747.117.274.86
   EV/EBIT(x)17.3119.059.8811.189.81
   EV/CE(x)1.411.691.621.400.80
   M Cap / Sales1.041.270.890.790.39
Growth Ratio
   Net Sales Growth(%)2.78-7.8320.358.5210.68
   Core EBITDA Growth(%)9.14-22.2635.778.1060.65
   EBIT Growth(%)-3.22-27.7950.3241.8074.31
   PAT Growth(%)-29.91-33.0092.19131.70222.66
   EPS Growth(%)-29.91-33.00-35.94131.71221.45
Financial Stability Ratios
   Total Debt/Equity(x)0.460.460.310.300.52
   Current Ratio(x)1.301.341.621.381.30
   Quick Ratio(x)0.780.841.130.860.91
   Interest Cover(x)2.554.337.443.321.79
   Total Debt/Mcap(x)0.290.230.170.200.69

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.